RenovoRx (RNXT)

• Market cap: $40.1M
• 1 day: -1.1%
• 5 days: 2.34%
• 1 month: -2.21%
• 3 months: -8.72%
• 6 months: -8.47%
• Year to date: 5.38%
• 1 year: -16.97%
• 5 years: -87.88%
• 10 years: -87.88%
• Sector: Healthcare
• Industry: Biotechnology

About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Employees: 17